A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy
Phase of Trial: Phase I/II
Latest Information Update: 31 Oct 2018
At a glance
- Drugs AMG 592 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Amgen
- 23 Oct 2018 Planned End Date changed from 4 Jan 2022 to 27 Feb 2022.
- 23 Oct 2018 Planned primary completion date changed from 25 Jun 2021 to 18 Aug 2021.
- 31 Aug 2018 Biomarkers information updated